Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Panmira Pharmaceuticals LLC

www.panmira.com

Latest From Panmira Pharmaceuticals LLC

Chiesi Takes Aim At Next-Generation Eosinophilic Asthma Therapy

Chiesi may be coming late to the development of eosinophilic asthma therapies, but there are certain advantages associated with acquisition target Atopix Therapeutics’ potential products that could strengthen the specialty pharma's already significant presence in the asthma market.

M & A Respiratory

Here To Stay: Inception Sciences Shows Why Build-To-Buy Works

Born at a time when venture capital found few exit opportunities for early-stage companies, build-to-buy helped mitigate the risk in investing in uncharted science. But the model is flourishing even in this period of wider capital options.

BioPharmaceutical Strategy

Biopharma Dealmaking Quarterly Statistics, Q4 2012

At $4.2 billion, biopharma financing in Q4 2012 showed a 36% increase over Q3 with FOPOs again dominating as the most popular deal type. With 34 finalized biopharma M&As, Q4 was the most active quarter of all 2012 for acquisitions. The 108 biopharma alliances completed had a combined potential deal value of almost $2 billion; Johnson & Johnson, with seven tie-ups, was the busiest pharmaco during Q4.

BioPharmaceutical Deals

Roche Enters Hearing-Loss Space In Risk-Sharing Venture With Inception, Versant

The newly formed Inception 3 will work to bring small molecule candidates for hearing loss, based on technology licensed from Stanford University, to IND-filing stage, at which point Roche will have the option to buy out the program.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Inflammation
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Panmira Pharmaceuticals LLC
  • Senior Management
  • Hari Kumar, PhD, CEO
  • Contact Info
  • Panmira Pharmaceuticals LLC
    Phone: (858) 875-4810
    9535 Waples St.
    Ste. 100
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register